The Virtual Cell: Revolutionizing Personalized Cancer Treatment Through AI-Powered Simulation
ISEF · 2025 Cellular and Molecular Biology
Overview
In vitro drug sensitivity testing is critical for identifying effective cancer treatments. However, due to the vast number of potential drug monotherapies and combination therapies, in vitro testing is hindered by inefficiencies in time, cost, and scalability. Moreover, solutions using in silico modeling have focused on pure AI-based methods, lacking extensibility outside their training data. To address these challenges, I developed The Virtual Cell, an AI-driven simulation model that predicts cellular drug response by integrating genomics, proteomics, and rate law-based biochemical simulation. The model employs a novel elementary reaction prediction algorithm to create an internal reaction network from literature-backed protein signaling pathways, modeling the intracellular biochemical interactions. The Virtual Cell is initialized with functional genomic data and quantitative proteomic data to run simulated drug sensitivity experiments measuring in silico viability. In vitro kinetic drug monotherapy experiments were conducted for Capivasertib, Alpelisib, Tamoxifen, and Fulvestrant across the MCF-7, T-47D, MDA-MB-231, and MDA-MB-468 breast cancer cell lines. The model's reaction parameters were calibrated with machine learning to align in silico predictions with in vitro viability. Once calibrated, The Virtual Cell was used to predict novel combination therapies, which are then tested in vitro for validation. The Virtual Cell has shown remarkable accuracy in simulating combination therapy, allowing for increased efficiency of identifying new synergistic combinations. Overall, The Virtual Cell has the potential to transform oncology by reducing reliance on costly in vitro testing, advancing personalized and precision treatment strategies, and improving patient outcomes.
Competition history
- ISEF 2025
Resources
Related projects
ISEF · 2026
The Virtual Cell 2.0: Expanding Precision and Personalized Cancer Therapy Through AI-Powered Simulation
ISEF · 2025
TETRA-C: Accelerating Cancer Therapy Through AI-Optimized Telomerase Inhibition, Enzymatic Targeting, and the Suppression of Metastasis
ISEF · 2023
Integrating Machine Learning with 3D Organoid Modeling to Identify Biomarkers to Combat Drug Resistance in Cancer
ISEF · 2024
Harnessing Heterotypic 3D Spheroid Culture Method for Pre-clinical Testing of Computationally Identified Biomarkers of Drug Resistance in Breast Cancer
Closest projects by meaning, across every fair and year in the corpus.
Source: Regeneron International Science and Engineering Fair